


Appendix A

AP 2005-0181 PTO 11 AUG 2006

Claim Amendments

1. (Currently amended) ~~Compounds A~~ A compound of formula 1



in which

R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy,
 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or
 completely or predominantly fluorine-substituted
 1-4C-alkoxy,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy,
 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or
 completely or predominantly fluorine-substituted
 1-4C-alkoxy,

or in which

R1 and R2 together are a 1-2C-alkylenedioxy group,

R3 is hydrogen or 1-4C-alkyl,

R31 is hydrogen or 1-4C-alkyl,

either, in a first embodiment (embodiment a) ~~according to the present invention,~~

R4 is -O-R41, in which

R41 is hydrogen, 1-4C-alkyl, completely or predominantly fluorine-substituted 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl or 1-7C-alkylcarbonyl, and

R5 is hydrogen or 1-4C-alkyl,

or, in a second embodiment (embodiment b) ~~according to the present invention,~~





R4 is hydrogen or 1-4C-alkyl, and

R5 is -O-R51, in which

R51 is hydrogen, 1-4C-alkyl, completely or predominantly fluorine-substituted 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl or 1-7C-alkylcarbonyl,

R6 is hydrogen, halogen, nitro, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R7 is a radical of formulae (a), (b), (c) or (d)



in which

if R7 is a radical of the formula (b),

either

R8, R9, R10 and R11 independently of one another are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, cyano, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28,

or

R8 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28,

R9 is ☐ hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28, and

R10 and R11, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, azonan-1-yl, azecan-1-yl, morpholin-4-yl, tetrahydroisoquinolin-2-yl, tetrahydro-6,7-dimethoxyisoquinolin-2-yl, 3,5-dimethyl-pyrazol-1-yl, pyrazol-1-yl, 2,6-dimethyl-morpholin-4-yl, 2,6-dimethyl-piperidin-1-yl, 4-benzyl-piperidin-1-yl, thiomorpholin-4-yl or 1H-1,2,4-triazol-1-yl radical, or a piperazin-1-yl radical substituted in 4-position by R19,

or

R8 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28,

R9 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28,

R10 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28, and

R11 is Aryl₁, naphthyl, phenyl, phenyl substituted by R20 and/or R21, phenyl-1-4C-alkyl or phenyl-1-4C-alkyl substituted by R22 and R23,

in which

if R7 is a radical of the formula (c),

either

R12, R13, R14 and R15 independently of one another are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28,

or

R12 and R13 independently of one another are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28, and

R14 and R15, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, azonan-1-yl, azecan-1-yl, morpholin-4-yl, tetrahydroisoquinolin-2-yl, tetrahydro-6,7-dimethoxyisoquinolin-2-yl, 3,5-dimethyl-pyrazol-1-yl, pyrazol-1-yl, 2,6-dimethyl-morpholin-4-yl, 2,6-dimethyl-piperidin-1-yl, 4-benzyl-piperidin-1-yl, thiomorpholin-4-yl or 1H-1,2,4-triazol-1-yl radical, or a piperazin-1-yl radical substituted in 4-position by R19,

or

R12 and R13, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, morpholino-4-yl, 4-(1-4C-alkyl)-piperazin-1-yl, 2,6-dimethyl-morpholin-4-yl, 2,6-dimethyl-piperidin-1-yl, 4-benzyl-piperidin-1-yl or thiomorpholin-4-yl radical, and

R14 and R15, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, morpholino-4-yl, 4-(1-4C-alkyl)-piperazin-1-yl, 2,6-dimethyl-morpholin-4-yl, 2,6-dimethyl-piperidin-1-yl, 4-benzyl-piperidin-1-yl or thiomorpholin-4-yl radical,

or

R12 and R15 independently of one another are hydrogen or 1-4C-alkyl, and

R13 and R14, together and with inclusion of the N-C(=)-N structure to which they are bonded, are a hexahydropyrimidin-2-ylidene or imidazolidin-2-ylidene radical,

in which

if R7 is a radical of the formula (d),

R16 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or R28, and

R17 and R18, together and with inclusion of the N-C(-)-N structure to which they are bonded are Aryl2,

Aryl1 is 4-methylthiazol-2-yl, benzimidazol-2-yl, 5-nitrobenzimidazol-2-yl, 5-chlorobenzimidazol-2-yl, 5-methylbenzimidazol-2-yl, 4-methylquinazolin-2-yl, benzothiazol-2-yl, benzoxazol-2-yl or pyrimidin-2-yl,

Aryl2 is 1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl, imidazol-2-yl, 4,5-dicyano-imidazol-2-yl, 4-methyl-imidazol-2-yl, 4-ethyl-benzimidazol-2-yl, 4-acetyl-imidazol-2-yl, 1H-[1,2,4]triazol-3-yl, benzimidazol-2-yl, 1-methyl-benzimidazol-2-yl, 1-ethyl-benzimidazol-2-yl, 5,6-dimethyl-benzimidazol-2-yl, purin-8-yl, 6-amino-7-methyl-7H-purine-8-yl, 1,6-dimethylimidazo[4,5-

b]pyridin-2-yl, 1,5,6-trimethylimidazo[4,5-b]pyridin-2-yl, 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione-8-yl, 7-ethyl-3-methyl-3,7-dihydro-purine-2,6-dione-8-yl, 1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione-8-yl, thiadiazolyl, 1,4-dihydrotetrazol-5-yl, 1H-[1,2,4]triazol-3-yl, 1,3-dihydrobenzimidazol-5-yl, 1H-tetrazol-5-yl, pyrimidin-2-yl or 4,6-dimethylpyrimidin-2-yl,

R19 is 1-4C-alkyl, formyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, 1-4C-alkoxycarbonyl-1-4C-alkyl, 1-4C-alkylcarbonyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, hydroxy-2-4C-alkoxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkoxy-2-4C-alkyl, phenyl, phenyl substituted by R24 and/or R25, [benzo(1,3)dioxol]-5-ylmethyl, phenyl-1-4C-alkyl or phenyl-1-4C-alkyl substituted in the phenyl moiety by R26 and/or R27,

R20 is halogen, nitro, carboxyl, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R21 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R22 is halogen, nitro, carboxyl, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R23 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R24 is halogen, nitro, carboxyl, 1-4C-alkyl, 1-4C-alkylcarbonyl, trifluoromethyl or 1-4C-alkoxy,

R25 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R26 is halogen, nitro, carboxyl, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R27 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R28 is R29(R30)N-2-4C-alkyl wherein

R29 and R30, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-(1-4C-alkyl)piperazin-1-yl, azepan-1-yl, azocan-1-yl, azonan-1-yl, azecan-1-yl, tetrahydroisoquinolin-2-yl, tetrahydro-6,7-dimethoxyisoquinolin-2-yl, 3,5-dimethyl-pyrazol-1-yl, pyrazol-1-yl, morpholin-4-yl, 2,6-dimethyl-morpholin-4-yl, 2,6-dimethyl-piperidin-1-yl, 4-benzyl-piperidin-1-yl, thiomorpholin-4-yl or 1H-1,2,4-triazol-1-yl radical,

or a salt, N-oxide, salt of the N-oxide, enantiomer, salt of the enantiomer, E/Z isomer, salt of the E/Z isomer, tautomer or salt of the tautomer thereof

~~the salts of these compounds, as well as the N oxides, enantiomers, E/Z isomers and tautomers of these compounds and their salts.~~

2. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is 1-2C-alkoxy, 3-5C-cycloalkoxy,
3-5C-cycloalkylmethoxy, 2,2-difluoroethoxy, or
completely or predominantly fluorine-substituted
1-2C-alkoxy,

R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy,
3-5C-cycloalkylmethoxy, 2,2-difluoroethoxy, or
completely or predominantly fluorine-substituted
1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen,

either, in a first embodiment (embodiment a) ~~according to~~
~~the present invention,~~

R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl, and

R5 is hydrogen,

or, in a second embodiment (embodiment b) ~~according to the~~
~~present invention,~~


R4 is hydrogen, and

R5 is -O-R51, in which

R51 is hydrogen or 1-4C-alkylcarbonyl,

R6 is hydrogen, halogen, nitro, 1-4C-alkyl, trifluoromethyl
or 1-4C-alkoxy,

R7 is a radical of formulae (a), (b), (c) or (d)



in which

if R7 is a radical of the formula (b),

either

R8 is hydrogen, and

R9, R10 and R11 independently of one another are
hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or
3-7C-cycloalkylmethyl,

or

R8 is hydrogen,

R9 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or 3-7C-
cycloalkylmethyl, and

R10 and R11, together and including the nitrogen atom
to which both are bonded, are a pyrrolidin-1-yl,
piperidin-1-yl, azepan-1-yl, azocan-1-yl, azonan-1-yl,
azecan-1-yl, morpholin-4-yl, tetrahydroisoquinolin-2-
yl, 3,5-dimethyl-pyrazol-1-yl, pyrazol-1-yl, 2,6-
dimethyl-morpholin-4-yl or 2,6-dimethyl-piperidin-1-yl
radical, or a piperazin-1-yl radical substituted in 4-
position by R19,

or

R8 is hydrogen,

R9 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl,

R10 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl, and

R11 is Aryl¹¹, naphthyl, phenyl, phenyl substituted by R20 and/or R21, phenyl-1-4C-alkyl or phenyl-1-4C-alkyl substituted by R22 and R23,

in which

if R7 is a radical of the formula (c),

either

R12, R13, R14 and R15 independently of one another are hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl,

or

R12 and R13 independently of one another are hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl, and

R14 and R15, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, azonan-1-yl, azecan-1-yl, morpholin-4-yl, tetrahydroisoquinolin-2-yl, 3,5-dimethyl-pyrazol-1-yl, pyrazol-1-yl, 2,6-

dimethyl-morpholin-4-yl or 2,6-dimethyl-piperidin-1-yl radical, or a piperazin-1-yl radical substituted in 4-position by R19,

or

R12 and R13, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, morpholino-4-yl, 4-(1-4C-alkyl-)-piperazin-1-yl, 2,6-dimethyl-morpholin-4-yl or 2,6-dimethyl-piperidin-1-yl radical, and

R14 and R15, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, morpholino-4-yl, 4-(1-4C-alkyl-)-piperazin-1-yl, 2,6-dimethyl-morpholin-4-yl or 2,6-dimethyl-piperidin-1-yl radical,

or

R12 and R15 independently of one another are hydrogen or 1-4C-alkyl, and

R13 and R14, together and with inclusion of the N-C(=)-N structure to which they are bonded, are a hexahydropyrimidin-2-ylidene or imidazolidin-2-ylidene radical,

in which

if R7 is a radical of the formula (d),

R16 is hydrogen, and

R17 and R18, together and with inclusion of the N-C(-)-N structure to which they are bonded are Aryl2,

Aryl1 is 4-methylthiazol-2-yl, benzimidazol-2-yl, 5-nitrobenzimidazol-2-yl, 5-chlorobenzimidazol-2-yl, 5-methylbenzimidazol-2-yl, benzothiazol-2-yl or benzoxazol-2-yl,

Aryl2 is 1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl, imidazol-2-yl, 4,5-dicyano-imidazol-2-yl, 4-methyl-imidazol-2-yl, 4-ethyl-benzimidazol-2-yl, 4-acetyl-imidazol-2-yl, 1H-[1,2,4]triazol-3-yl, benzimidazol-2-yl, 1-methyl-benzimidazol-2-yl, 1-ethyl-benzimidazol-2-yl, 5,6-dimethyl-benzimidazol-2-yl, purin-8-yl, 6-amino-7-methyl-7H-purine-8-yl, 1,6-dimethylimidazo[4,5-b]pyridin-2-yl, 1,5,6-trimethylimidazo[4,5-b]pyridin-2-yl, 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione-8-yl, 7-ethyl-3-methyl-3,7-dihydro-purine-2,6-dione-8-yl, 1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione-8-yl or 1H-[1,2,4]triazol-3-yl,

R19 is 1-4C-alkyl, formyl, 1-4C-alkylcarbonyl, 2-hydroxyethyl, phenyl, phenyl substituted by R24 and/or R25, phenyl-1-4C-alkyl or phenyl-1-4C-alkyl substituted in the phenyl moiety by R26 and/or R27,

R20 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,

R21 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R22 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,
 R23 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
 R24 is halogen, nitro, carboxyl, 1-4C-alkyl or 1-4C-alkoxy,
 R25 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
 R26 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,
 R27 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
or a salt, N-oxide, salt of the N-oxide, enantiomer, salt
of the enantiomer, E/Z isomer, salt of the E/Z isomer,
tautomer or salt of the tautomer thereof
~~the salts of these compounds, as well as the N-oxides,~~
~~enantiomers, E/Z isomers and tautomers of these compounds~~
~~and their salts.~~

3. (Currently amended) ~~Compounds~~ A compound of formula 1
 according to claim 1 in which

R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or
 predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or
 predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen,

either, in a first embodiment (embodiment a) ~~according to~~
~~the present invention,~~

R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl, and

R5 is hydrogen,

or, in a second embodiment (embodiment b) ~~according to the present invention,~~


R4 is hydrogen, and


R5 is -O-R51, in which

R51 is hydrogen or 1-4C-alkylcarbonyl,

R6 is hydrogen,

R7 is a radical selected from





or a salt, N-oxide, salt of the N-oxide, enantiomer, salt of the enantiomer, E/Z isomer, salt of the E/Z isomer, tautomer or salt of the tautomer thereof

~~the salts of these compounds, as well as the N oxides, enantiomers, E/Z isomers and tautomers of these compounds and their salts.~~

4. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is 1-2C-alkoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, or predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen,


R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl, and

R5 is hydrogen,

R6 is hydrogen,

R7 is a radical of formula (c)



in which

either

R12 is hydrogen,

R13 is hydrogen,

R14 is hydrogen or 1-4C-alkyl, and

R15 is 1-4C-alkyl or 3-7C-cycloalkyl,

or

R12 is hydrogen,

R13 is hydrogen, and

R14 and R15, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, azonan-1-yl or morpholin-4-yl, radical, or a piperazin-1-yl radical substituted in 4-position by R19, in which

R19 is 1-4C-alkylcarbonyl,

or a salt, N-oxide, salt of the N-oxide, enantiomer, salt of the enantiomer, E/Z isomer, salt of the E/Z isomer, tautomer or salt of the tautomer thereof

~~the salts of these compounds, as well as the N-oxides, enantiomers, E/Z isomers and tautomers of these compounds and their salts.~~

5. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is methoxy, or ethoxy,

R2 is methoxy, ethoxy, 2,2-difluoroethoxy, or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen,


R4 is -O-R41, in which

R41 is hydrogen, and

R5 is hydrogen,

R6 is hydrogen,

R7 is bonded to the meta or para position with respect to the binding position in which the phenyl ring is bonded to the phenanthridine ring system, and is a radical of formula (c)



in which

either

R12 is hydrogen,

R13 is hydrogen,

R14 is 1-4C-alkyl, ~~such as e.g. 1-2C alkyl,~~ and

R15 is 1-4C-alkyl, ~~such as e.g. 1-2C alkyl,~~

or

R12 is hydrogen,

R13 is hydrogen,

R14 is hydrogen, and

R15 is 3-5C-cycloalkyl, ~~such as e.g. cyclopropyl,~~

or

R12 is hydrogen,

R13 is hydrogen, and

R14 and R15, together and including the nitrogen atom to which both are bonded, are a pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocan-1-yl, azonan-1-yl or morpholin-4-yl radical, or a piperazin-1-yl radical substituted in 4-position by R19, in which

R19 is 1-4C-alkylcarbonyl,

or a salt, N-oxide, salt of the N-oxide, enantiomer, salt of the enantiomer, E/Z isomer, salt of the E/Z isomer, tautomer or salt of the tautomer thereof

~~the salts of these compounds, as well as the N oxides, enantiomers, E/Z isomers and tautomers of these compounds and their salts.~~

6. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy, or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,


R4 is -O-R41, in which

R41 is hydrogen, and

R5 is hydrogen,

R6 is hydrogen,

R7 is bonded to the meta or para position with respect to the binding position in which the phenyl ring is bonded to the phenanthridine ring system, and is a radical of formula (c)



in which

either

R12 is hydrogen,

R13 is hydrogen,

R14 is ethyl, and

R15 is ethyl,

or

R12 is hydrogen,

R13 is hydrogen,

R14 is hydrogen, and

R15 is cyclopropyl,

or

R12 is hydrogen,

R13 is hydrogen, and

R14 and R15, together and including the nitrogen atom to which both are bonded, are an azocan-1-yl radical, or a piperazin-1-yl radical substituted in 4-position by R19, in which

R19 is acetyl,

or a salt, N-oxide, salt of the N-oxide, enantiomer, salt of the enantiomer, E/Z isomer, salt of the E/Z isomer, tautomer or salt of the tautomer thereof


~~the salts of these compounds, as well as the N oxides, enantiomers, E/Z isomers and tautomers of these compounds and their salts.~~

7. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 selected from the group consisting of

1. N'-(1-{4-[(2RS,4aRS,10bRS)-9-(1,1-Difluoro-methoxy)-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl]-phenyl}-methanoyl)-N,N-diethyl-guanidine,
2. N-(1-Amino-1-azocan-1-yl-methylene)-4-[(2RS,4aRS,10bRS)-9-(1,1-difluoro-methoxy)-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl]-benzamide,
3. N-Cyclopropyl-N'-(1-{4-[(2RS,4aRS,10bRS)-9-(1,1-difluoro-methoxy)-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl]-phenyl}-methanoyl)-guanidine,
4. N-[1-(4-Acetyl-piperazin-1-yl)-1-amino-methylene]-4-((2RS,4aRS,10bRS)-2-hydroxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzamide,
5. N,N-Diethyl-N'-{1-[4-((2RS,4aRS,10bRS)-2-hydroxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-phenyl]-methanoyl}-guanidine, [[and]]
6. N-(1-Amino-1-azocan-1-yl-methylene)-4-((2RS,4aRS,10bRS)-2-hydroxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzamide,
and the salts, N-oxides, salts of the N-oxides, enantiomers, salts of the enantiomers, E/Z isomers, salts of the E/Z isomers, tautomers and salts of the tautomers thereof

~~the salts of these compounds, as well as the N-oxides, enantiomers, E/Z isomers and tautomers of these compounds and their salts.~~

8. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 ~~any of the preceding claims~~, which have with respect to the positions 4a and 10b the configuration shown in formula 1*:





or a salt, N-oxide, salt of the N-oxide, enantiomer, salt of the enantiomer, E/Z isomer, salt of the E/Z isomer, tautomer or salt of the tautomer thereof

~~the salts of these compounds, as well as the N-oxides, enantiomers, E/Z isomers and tautomers of these compounds and their salts.~~

9. (Currently amended) ~~Compounds~~ A compound of formula 1 according to claim 1 ~~any of the preceding claims~~, which

have with respect to the positions 2, 4a and 10b, or, respectively, 3, 4a and 10b the configuration shown either in formula 1a***** or in formula 1b*****:



or a salt, N-oxide, salt of the N-oxide, E/Z isomer, salt
of the E/Z isomer, tautomer or salt of the tautomer thereof
~~the salts of these compounds, as well as the N oxides, E/Z~~
~~isomers and tautomers of these compounds and their salts.~~

10. (Canceled)

11. (Currently amended) A pharmaceutical composition comprising one or more compounds of formula 1 according to claim 1, or a pharmaceutically acceptable salt, N-oxide, salt of an N-oxide, enantiomer, salt of an enantiomer, E/Z isomer, salt of an E/Z isomer, tautomer or salt of a tautomer thereof, together with a pharmaceutically acceptable excipient, diluent and/or vehicle ~~customary pharmaceutical excipients, diluents and/or vehicles.~~

12. (Canceled)

13. (Currently amended) A method for treating illnesses in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula 1 as claimed in claim 1, or a pharmaceutically acceptable salt, N-oxide, salt of an N-oxide, enantiomer, salt of an enantiomer, E/Z isomer, salt of an E/Z isomer, tautomer or salt of a tautomer thereof.

14. (Currently amended) A method for treating an airway ~~disorders~~ disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula 1 as claimed in claim 1, or a

pharmaceutically acceptable salt, N-oxide, salt of an N-oxide, enantiomer, salt of an enantiomer, E/Z isomer, salt of an E/Z isomer, tautomer or salt of a tautomer thereof.